The drug regulator has issued a notice to Mumbai-based Glenmark Pharma seeking a clarification against a complaint that the company is selling its recently approved Covid-19 drug Fabiflu at an “unaffordable” price and with “false claims” that it can be effective for patients with co-morbidities. The notice from the Drugs Controller General of India is based on a complaint from a Member of Parliament.
Read more here:: India News Times